DBV TECHNOLOGIES (EPA:DBV) | WebDisclosure

Basculer en Français

8597	Companies
140147	Keywords
76066	Articles
74831	Press releases

Home
Companies
DBV TECHNOLOGIES

PRESS RELEASE

published on 03/28/2025 at 03:30, 6 days 9 hours ago

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
DBV Technologies secures financing of up to $306.9 million (€284.5 million) to advance Viaskin Peanut Patch through FDA submission and US commercial launch. Investors include MPM BioImpact, Adage Capital Management, Janus Henderson Investors, and more

Financing Commercial Launch DBV Technologies FDA Submission Viaskin Peanut Patch
PRESS RELEASE

published on 03/28/2025 at 03:30, 6 days 9 hours ago

DBV Technologies Annonce un Financement pouvant atteindre 306,9 millions de dollars (284,5 millions d’euros) permettant d’avancer le programme Viaskin® Peanut jusqu’au dépôt d'une Demande de Licence Biologique (BLA) et d’assurer la...
BRIEF

published on 03/24/2025 at 07:35, 10 days 4 hours ago

DBV Technologies anticipe une avancée réglementaire avec la FDA

DBV Technologies Viaskin Peanut Trésorerie 2024 FDA Accord Étude VITESSE
BRIEF

published on 03/24/2025 at 07:35, 10 days 4 hours ago

DBV Technologies Anticipates Regulatory Progress with the FDA

FDA Agreement DBV Technologies Viaskin Peanut Treasury 2024 SPEED Study
PRESS RELEASE

published on 03/24/2025 at 07:30, 10 days 5 hours ago

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...
DBV Technologies secures FDA agreement for Viaskin Peanut Patch BLA submission in 4-7-year-olds, accelerating launch timeline by approximately one year. Unaudited 2024 financial results reported

FDA Agreement DBV Technologies Unaudited Financial Results Viaskin Peanut Patch BLA Submission
PRESS RELEASE

published on 03/24/2025 at 07:30, 10 days 5 hours ago

DBV Technologies conclut un accord avec la FDA sur les données d'innocuité requises pour la demande de BLA du patch Viaskin® Peanut chez les enfants de 4-7 ans, accélérant ainsi au premier semestre 2026 le dépôt de la demande…
DBV Technologies conclut un accord avec la FDA sur les données d'innocuité du patch Viaskin Peanut, anticipant un dépôt au 1er semestre 2026, et publie ses résultats financiers 2024

Résultats Financiers FDA DBV Technologies Viaskin Peanut Innocuité
BRIEF

published on 02/25/2025 at 22:06, 1 month 5 days ago

DBV Technologies au congrès AAAAI/WAO pour présenter des avancées sur l'allergie à l'arachide

Étude Clinique DBV Technologies Allergie À L'arachide Patch VIASKIN® Congrès AAAAI/WAO
BRIEF

published on 02/25/2025 at 22:06, 1 month 5 days ago

DBV Technologies at AAAAI/WAO Congress to Present Advances in Peanut Allergy

Clinical Study DBV Technologies Peanut Allergy AAAAI/WAO Congress VIASKIN® Patch
PRESS RELEASE

published on 02/25/2025 at 22:01, 1 month 5 days ago

DBV Technologies participera au prochain congrès conjoint AAAAI/WAO
DBV Technologies participera au prochain congrès conjoint AAAAI/WAO en présentant les résultats de l'étude sur l'immunothérapie épicutanée avec VIASKIN® peanut pour les enfants allergiques à l'arachide

Immunothérapie DBV Technologies Viaskin Peanut Congrès Conjoint AAAAI/WAO
PRESS RELEASE

published on 02/25/2025 at 22:01, 1 month 5 days ago

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
DBV Technologies to participate in AAAAI/WAO Joint Congress to present long-term efficacy results of epicutaneous immunotherapy with VIASKIN peanut patch in peanut-allergic children aged 4-11 years, showcasing treatment benefits and high compliance rates

DBV Technologies Epicutaneous Immunotherapy Viaskin Peanut Patch AAAAI/WAO Joint Congress PEPITES Study

Accesswire

Published on 04/03/2025 at 11:00, 1 hour 30 minutes ago

Focus Graphite Advanced Materials Initiates Validation Testing of Lac Knife Anode Materials with Leading Battery Innovator C4V
Published on 04/03/2025 at 05:10, 7 hours 20 minutes ago

Battery X Metals Announces Corporate Awareness Agreement
Published on 04/03/2025 at 01:35, 10 hours 55 minutes ago

GMV Minerals Inc. Closes Non-Brokered Financing/ Engages Investor Relations Firm
Published on 04/02/2025 at 23:35, 12 hours 55 minutes ago

Murchison Minerals to Seek Shareholders’ Approval for Share Consolidation
Published on 04/02/2025 at 20:00, 16 hours 30 minutes ago

Network-1 Announces Acquisition of Patent Portfolio

View all ACCESSWIRE

EQS Group

Published on 04/03/2025 at 12:15, 15 minutes ago

Baisha’s San Yue San Festival: International Students Immersed in Vibrant Ethnic Culture
Published on 04/03/2025 at 12:00, 30 minutes ago

Linde Announces First Quarter 2025 Earnings and Conference Call Schedule
Published on 04/03/2025 at 11:42, 48 minutes ago

Resolutions of the 2025 annual general meeting of Ørsted A/S
Published on 04/03/2025 at 11:15, 1 hour 15 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 04/03/2025 at 09:00, 3 hours 30 minutes ago

Partners Group to invest in Gestcompost, the largest organic waste manager in Spain, through a continuation fund

Les Echos

Published on 04/03/2025 at 09:45, 2 hours 44 minutes ago

GUILLEMOT CORPORATION: Information regarding the total number of voting rights and shares 31/03/2025
Published on 04/03/2025 at 09:45, 2 hours 44 minutes ago

GUILLEMOT CORPORATION : Informations relatives au nombre total de droits de vote et d’actions 31/03/2025
Published on 04/03/2025 at 09:35, 2 hours 54 minutes ago

Déclaration du nombre d’actions et droits de vote au 31 mars 2025
Published on 04/03/2025 at 09:35, 2 hours 54 minutes ago

Disclosure of Share Capital and Voting Rights as of March 31, 2025
Published on 04/03/2025 at 08:45, 3 hours 45 minutes ago

BAIKOWSKI : Rapport financier annuel 2024

View all LES ECHOS COMFI WIRE